TrivarX Completes Phase 2 Sleep Signal Analysis for Current Major Depressive Episode Study; Shares Surge 11%

MT Newswires Live07-10

Mental health technology company TrivarX (ASX:TRI) completed phase 2 of its Sleep Signal Analysis for Current Major Depressive Episode study using its AI-backed algorithm, MEB-001, according to a Wednesday filing with the Australian Securities Exchange.

The study aims to validate MEB-001 for screening and diagnosing major depressive episodes in test subjects, with data from 400 enrolled patients currently being assessed, the filing said.

The study's results will provide additional regulatory validation for MEB-001 before further engagement with the US Food and Drug Administration in the coming months, the company said.

Shares rose nearly 11% in morning trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2450788207?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-10 10:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2450788207","market":"nz","top_or_hot":-1,"title":"TrivarX Completes Phase 2 Sleep Signal Analysis for Current Major Depressive Episode Study; Shares Surge 11%","media":"MT Newswires Live","content":"<html><body><p> Mental health technology company TrivarX (ASX:TRI) completed phase 2 of its Sleep Signal Analysis for Current Major Depressive Episode study using its AI-backed algorithm, MEB-001, according to a Wednesday filing with the Australian Securities Exchange.</p><p>The study aims to validate MEB-001 for screening and diagnosing major depressive episodes in test subjects, with data from 400 enrolled patients currently being assessed, the filing said.</p><p>The study's results will provide additional regulatory validation for MEB-001 before further engagement with the US Food and Drug Administration in the coming months, the company said.</p><p>Shares rose nearly 11% in morning trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TrivarX Completes Phase 2 Sleep Signal Analysis for Current Major Depressive Episode Study; Shares Surge 11%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTrivarX Completes Phase 2 Sleep Signal Analysis for Current Major Depressive Episode Study; Shares Surge 11%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-10 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Mental health technology company TrivarX (ASX:TRI) completed phase 2 of its Sleep Signal Analysis for Current Major Depressive Episode study using its AI-backed algorithm, MEB-001, according to a ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TRI.AU","symbol_name":"TRIVARX FPO","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2450788207","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2450788207","pubTimestamp":1720578025,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mental health technology company TrivarX  completed phase 2 of its Sleep Signal Analysis for Current Major Depressive Episode study using its AI-backed algorithm, MEB-001, according to a Wednesday filing with the Australian Securities Exchange.The study aims to validate MEB-001 for screening and diagnosing major depressive episodes in test subjects, with data from 400 enrolled patients currently being assessed, the filing said.The study's results will provide additional regulatory validation for MEB-001 before further engagement with the US Food and Drug Administration in the coming months, the company said.Shares rose nearly 11% in morning trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TRI.AU":"TRIVARX FPO","BK7094":"医疗保健技术"},"translate_title":"TrivarX完成当前重度抑郁发作研究的2期睡眠信号分析；股价飙升11%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRI.AU":0.9},"content_text":"Mental health technology company TrivarX (ASX:TRI) completed phase 2 of its Sleep Signal Analysis for Current Major Depressive Episode study using its AI-backed algorithm, MEB-001, according to a Wednesday filing with the Australian Securities Exchange.The study aims to validate MEB-001 for screening and diagnosing major depressive episodes in test subjects, with data from 400 enrolled patients currently being assessed, the filing said.The study's results will provide additional regulatory validation for MEB-001 before further engagement with the US Food and Drug Administration in the coming months, the company said.Shares rose nearly 11% in morning trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2450788207"}